Actively Recruiting
Phase 1b Study to Test Safety and Effects of DNL628 in Adults With Early Alzheimers Disease
Led by Denali Therapeutics Inc. · Updated on 2026-07-01
68
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating DNL628 in a Phase 1b, multicenter, randomized, placebo-controlled, double-blind study involving participants with early Alzheimers disease, which includes mild cognitive impairment or mild Alzheimers with biomarker evidence of amyloid positivity. The study aims to assess the safety, tolerability, pharmacokinetics how the drug moves in the body, and pharmacodynamics how the drug affects the body of DNL628. In the Netherlands, an open-label extension phase is included. Participants will receive multiple ascending doses of either DNL628 or a placebo to evaluate different dosage levels. The study is conducted in a sequential design, meaning participants receive treatments in a set order. The dosing and assessment will occur over a 37-week double-blind period, with some locations offering an additional open-label phase. Throughout the study, participants will be monitored for treatment-emergent adverse events and drug levels in the blood at various times. Researchers will also measure changes in biomarkers related to Alzheimers disease, such as total tau and ptau181 in cerebrospinal fluid. The total participation time covers the 37 weeks of the double-blind period, with safety and drug effects carefully tracked during this time.
CONDITIONS
Brief Title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
Research Team
C
Clinical Trials at Denali Therapeutics
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here